In:
Cancer, Wiley, Vol. 117, No. 20 ( 2011-10-15), p. 4779-4787
Abstract:
Median progression‐free survival (8.4 vs 5.2 months; P = .003), overall survival (17.9 vs 11.3 months; P = .013), and extrahepatic metastasis‐free survival (13.8 vs 5.7 months; P 〈 .001) were found to be significantly longer in subjects with low maximal tumor standardized uptake values (SUVs 〈 6.1) than in those with high maximal tumor SUVs (≥6.1), in patients with locally advanced hepatocellular carcinoma (HCC) who underwent localized concurrent chemoradiation therapy. Similar results were obtained for the ratio of maximal tumor SUV to maximal normal liver SUV ( 〈 2 vs ≥2) concerning progression, death, and extrahepatic metastasis. Thus, tumor metabolic activity assessed by 18 F‐fluorodeoxyglucose uptake on positron emission tomography may be useful not only in predicting prognosis and treatment responses, but also in establishing optimal treatment plans in HCC patients.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v117.20
Language:
English
Publisher:
Wiley
Publication Date:
2011
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink